Welcome to our dedicated page for Halozyme Thrp news (Ticker: HALO), a resource for investors and traders seeking the latest updates and insights on Halozyme Thrp stock.
Halozyme Therapeutics, Inc. (HALO) generates news that spans drug delivery technology, clinical applications, strategic collaborations and corporate finance. As a biopharmaceutical company focused on subcutaneous administration of biologics, Halozyme’s announcements often highlight how its ENHANZE and Hypercon platforms are being integrated into partner therapies and new indications.
News items frequently cover collaboration and license agreements with global pharmaceutical and biotechnology companies. Examples include agreements with Takeda to use ENHANZE with vedolizumab and with Merus to develop a subcutaneous formulation of petosemtamab. These stories typically describe upfront payments, potential milestones and royalty structures, as well as the therapeutic areas targeted by ENHANZE-enabled products.
Another major category of HALO news involves regulatory milestones achieved by partner products that incorporate Halozyme technologies. Recent press releases describe U.S. Food and Drug Administration approvals for DARZALEX Faspro and RYBREVANT FASPRO, both co-formulated with ENHANZE, in multiple myeloma and EGFR-mutated non-small cell lung cancer. Such updates provide insight into how Halozyme’s platforms translate into commercial products and expanded indications.
Halozyme also issues updates on intellectual property and legal matters, including patent enforcement actions related to its MDASE portfolio and court decisions affecting subcutaneous formulations of other companies’ drugs. In addition, investors can follow corporate developments such as acquisitions, including the purchase of Elektrofi and its Hypercon technology, board appointments, executive transitions and participation in healthcare conferences.
For investors and industry observers, the HALO news feed offers a way to track the evolution of Halozyme’s partnership base, the progress of ENHANZE- and Hypercon-enabled products, and key events that may influence the company’s royalty outlook and strategic direction.
Halozyme announced that the European Commission has approved Roche's OCREVUS® SC, co-formulated with Halozyme's ENHANZE® enzyme, for treating relapsing and primary progressive multiple sclerosis. This new subcutaneous injection offers a 10-minute administration alternative to the traditional intravenous infusion, maintaining the same twice-yearly schedule. The approval is based on Phase III OCARINA II trial data, demonstrating comparable efficacy and safety between the SC and IV formulations. This new option aims to improve patient accessibility and treatment flexibility.
Halozyme Therapeutics announced that argenx received FDA approval for VYVGART® Hytrulo, co-formulated with Halozyme's ENHANZE®, for treating chronic inflammatory demyelinating polyneuropathy (CIDP). This is the first neonatal Fc receptor blocker approved as a subcutaneous injection for CIDP. The ADHERE study, the largest clinical trial on CIDP, showed a 69% clinical improvement rate and a 61% reduction in relapse risk compared to placebo. This is the second FDA-approved indication for VYVGART® Hytrulo with ENHANZE®, the first being for generalized myasthenia gravis. The safety profile remained generally consistent with previous studies.
Halozyme Therapeutics (NASDAQ: HALO) has raised its full-year 2024 financial guidance and updated its 5-year financial outlook, driven by a new European patent for its ENHANZE® drug delivery platform. The European Patent No. 4269578 will be validated in 37 countries and extends until March 6, 2029. This patent ensures the original royalty rate for DARZALEX SC in Europe, leading to increased revenue projections.
For 2024, Halozyme forecasts total revenue of $935 million to $1.015 billion, up 13% to 22% from 2023. Royalty revenue is expected to reach $520 million to $555 million, a 16% to 24% increase. Adjusted EBITDA is projected between $555 million and $615 million, a 30% to 44% growth, and non-GAAP diluted EPS is anticipated to range from $3.65 to $4.05, representing a 32% to 46% rise. The company's investor call on June 6 will provide further details.
Halozyme Therapeutics announced the issuance of European Patent No. 4269578 for its ENHANZE® drug delivery platform. The patent, covering the ENHANZE® rHuPH20 product, extends protection until March 6, 2029, and will be validated in 37 European countries.
This strengthens Halozyme's patent portfolio and maintains the original royalty rate for DARZALEX SC in Europe through March 2029. The new patent does not impact royalties for other ENHANZE® licenses, as their rates already extend beyond 2029.
Halozyme will discuss the new patent and update its 2024 financial guidance and 5-year financial outlook in a conference call on June 6, 2024, at 8:30am ET.
Halozyme Therapeutics (NASDAQ: HALO) announced that CEO Dr. Helen Torley will present and host investor meetings at the Goldman Sachs 45th Annual Global Healthcare Conference.
The presentation is scheduled for June 11, 2024, at 6:20 a.m. PT / 9:20 a.m. ET. A live audio webcast of the presentation will be available on the Investor Relations section of Halozyme's website. Replays will be accessible for 90 days post-conference.
Halozyme Therapeutics announced that Bristol Myers Squibb received an updated Prescription Drug User Fee Act (PDUFA) goal date from the U.S. FDA for their Biologics License Application. This application pertains to the subcutaneous formulation of Opdivo (nivolumab) co-formulated with Halozyme's ENHANZE (rHuPH20). The new target date is December 29, 2024. This formulation aims to cover all previously approved adult, solid tumor Opdivo indications, either as monotherapy or in combination treatment. The application is based on the CheckMate-67T Phase 3 trial, which showed noninferior pharmacokinetics, efficacy, and consistent safety compared to the intravenous version. If approved, it will be the first subcutaneous PD-1 inhibitor.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be participating in upcoming investor conferences with Nicole LaBrosse, the Chief Financial Officer, presenting and hosting investor meetings. The company will be at The Citizens JMP Life Sciences Conference on May 14, 2024, and the Benchmark 2024 Healthcare House Call Virtual Conference on May 21 and May 22, 2024. The presentations will be available via live audio webcasts on the Company's Investor Relations section.
Halozyme reported strong financial performance for the first quarter of 2024 with revenue increasing 21% YoY to $196 million, net income of $77 million, and adjusted EBITDA of $116 million. The company also announced a $750 million share repurchase program and reiterated its 2024 financial guidance, expecting total revenue of $915 - $985 million, representing YOY growth of 10% - 19%, adjusted EBITDA of $535 - $585 million, and non-GAAP diluted EPS of $3.55 - $3.90, showing YOY growth of 28% - 41%. Halozyme's CEO highlighted ongoing partnerships with argenx and Roche, as well as advancements in its ENHANZE technology.
Summary not available.
Summary not available.